Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03741166 · ClinicalTrials.gov registry record
Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.
A clinical trial of Colorectal Cancer, sponsored by Exact Sciences Corporation.
- Completed
- Registry status
- 871
- Enrollment target
- 20
- Study locations
NCT03741166: Completed study of Colorectal Cancer, sponsored by Exact Sciences Corporation.
NCT03741166 is a study of Colorectal Cancer that has completed, run by Exact Sciences Corporation. The registered enrollment target is 871 participants, below the 1,542-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03741166, a study of Colorectal Cancer, has completed, sponsored by Exact Sciences Corporation.
- COMPLETED
- Registry status
- 871 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this sub-study, 2018-10B, is to collect blood specimens to assess new biomarkers for the detection of Colorectal Cancer (CRC).
Primary Outcome
Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in blood from subjects at average risk for development of colorectal cancer.
Conditions Studied
Interventions
- OTHER Blood Sample Collection
Study Locations (20)
California
- Ventura County Gastroenterology - Camarillo
- Alliance Research Centers - Laguna Hills
- Focilmed - Oxnard
- Desert Oasis Healthcare Medical Group - Palm Springs
Louisiana
- New Orleans Research Institue - Metairie
- Delta Research Partners, LLC - Monroe
- Louisiana Research Center - Shreveport
Maryland
- Investigative Clinical Research - Annapolis
- Centennial Medical Group - Elkridge
- Capitol Research - Rockville
Connecticut
- Gastroenterology Associates of Fairfield County - Bridgeport
- Yale University Section of Digestive Diseases and Liver Diseases - New Haven
Illinois
- Northshore University Health System Evanston Hospital - Evanston
- DM Clinical Research- Southwest Gastroenterology - Oak Lawn
Indiana
- Deaconess Clinic- Mt. Pleasant - Evansville
- Deaconess Clinic- Gateway - Newburgh
Arizona
- Mayo Clinic Arizona - Phoenix
Florida
- Precision Clinical Research, LLC - Lauderdale Lakes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 871 participants |
| Start Date | 2018-11-08 |
| Est. Completion | 2019-04-05 |
What the finished NCT03741166 record still lists
NCT03741166 is an observational study that tracks outcomes without assigning an intervention. The registered 871 participants enrollment target is mid-sized for trials with a published cap, below the 1,542-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood Sample Collection is the first listed.
NCT03741166 names 20 study sites across 10 states, led by California, Louisiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT03741166 about?
NCT03741166 is a clinical study titled "Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.". The primary objective of this sub-study, 2018-10B, is to collect blood specimens to assess new biomarkers for the detection of Colorectal Cancer (CRC).
What is the current status of trial NCT03741166?
This trial is currently completed. The enrollment target is 871 participants. The study started on 2018-11-08. Estimated completion is 2019-04-05.
What conditions does trial NCT03741166 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT03741166?
The interventions under investigation include: Blood Sample Collection (OTHER).
Who is sponsoring clinical trial NCT03741166?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03741166 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03741166's enrollment target sits among peer trials
871 55th of 381 higher than 327 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI